TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30463829

Group type: EXPERIMENTAL
Intervention: S-1 monotherapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Capecitabine monotherapy
Number of subjects: 180
Study: 27250349

Group type: EXPERIMENTAL
Intervention: Experimental treatment 1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Experimental treatment 2
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 40
Study: 24688254

Group type: EXPERIMENTAL
Intervention: Schirmer's test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tear film break up time (TBUT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Goblet cell density (GCD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjunctival impression cytology (CIC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Correlation coefficient for Schirmer's test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Correlation coefficient for TBUT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Correlation coefficient for Rose Bengal scores (RBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Correlation coefficient for GCD
Number of subjects: 0
Study: 23009892

Group type: EXPERIMENTAL
Intervention: 1% rebamipide
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: 2% rebamipide
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 20382859

Group type: EXPERIMENTAL
Intervention: S. typhus vaccination
Number of subjects: 12
Study: 18924053

Group type: EXPERIMENTAL
Intervention: Telephone intervention (weekly phone calls discussing physical activity)
Number of subjects: 42
Study: 16118830

Group type: EXPERIMENTAL
Intervention: Cyamemazine (100-300 mg, administered at hourly intervals on day 1, then twice a day in decreasing doses)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Diazepam (10 mg, administered at hourly intervals on day 1, then twice a day in decreasing doses)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Cyamemazine
Number of subjects: 89
Study: 11858980

Group type: EXPERIMENTAL
Intervention: Chemotherapy trials conducted by EORTC STBSG
Number of subjects: 2500
Study: 10359474

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 423

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 423
Study: 8749839

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 8476892

Group type: COMPARATOR
Intervention: Triple-drug immunotherapy with cyclosporine started before surgery (group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OKT3 for 4 to 6 days after surgery with oral cyclosporine started between days 2 and 4 (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OKT3 (group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (group 1 and group 2)
Number of subjects: 30
Study: 3080012

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sotalol (160 mg twice daily)
Number of subjects: 20
Study: 30055597

Group type: EXPERIMENTAL
Intervention: Complex intervention consisting of assessment of performance of daily activities, defining a rehabilitation plan, and a follow-up home visit the day after discharge.
Number of subjects: 0
Study: 27268572

Group type: EXPERIMENTAL
Intervention: Performance feedback with multiple exemplar training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Performance feedback without generality programming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly writing practice alone
Number of subjects: 0
Study: 24493100

Group type: COMPARATOR
Intervention: Intensive blood pressure (BP) lowering (systolic BP goal of less than 120 mm Hg)
Number of subjects: 2977

Group type: COMPARATOR
Intervention: Fibrate therapy
Number of subjects: 2977

Group type: COMPARATOR
Intervention: Standard blood pressure (BP) lowering (systolic BP goal of less than 140 mm Hg)
Number of subjects: 2977

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2977
Study: 22810111

Group type: EXPERIMENTAL
Intervention: EUS‐CD
Number of subjects: 25

Group type: COMPARATOR
Intervention: PTBD
Number of subjects: 25
Study: 20818876

Group type: EXPERIMENTAL
Intervention: Tai chi
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (wellness education and stretching)
Number of subjects: 66
Study: 18923307

Group type: EXPERIMENTAL
Intervention: PUMC classification
Number of subjects: 62

Group type: COMPARATOR
Intervention: Lenke classification
Number of subjects: 62
Study: 15811593

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 12627312

Group type: EXPERIMENTAL
Intervention: MLSS I
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MLSS II
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MLSS III
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Workload at MLSS III
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Workload at MLSS I
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Workload at MLSS II
Number of subjects: 26
Study: 9428875

Group type: EXPERIMENTAL
Intervention: ATP (100 micrograms.kg‐1.min‐1)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 102
Study: 8036656

Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bed nets
Number of subjects: 350

Group type: COMPARATOR
Intervention: Non-treated nets
Number of subjects: 350
Study: 2972209

Group type: EXPERIMENTAL
Intervention: Orally administered combined hormones
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Percutaneous hormones
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 30176379

Group type: EXPERIMENTAL
Intervention: Kinesiotape (KT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Athletic tape (AT)
Number of subjects: 20
Study: 28929131

Group type: EXPERIMENTAL
Intervention: Dopamine agonist bromocriptine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dopamine D2 receptor availability assessed with PET-[18F]fallypride
Number of subjects: 20
Study: 25948722

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 43

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 43
Study: 24143890

Group type: EXPERIMENTAL
Intervention: Cognitive‐reminiscence therapy (six sessions of weekly, individual psychotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (support from the youth mental health service according to usual procedures)
Number of subjects: 0
Study: 21165702

Group type: EXPERIMENTAL
Intervention: DAO capsules
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 18438933

Group type: EXPERIMENTAL
Intervention: Progressive resistance training program for the musculature of the shoulder, held twice a week for 2 months.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (waiting list).
Number of subjects: 60
Study: 17070254

Group type: EXPERIMENTAL
Intervention: 60 shock waves per minute
Number of subjects: 100

Group type: COMPARATOR
Intervention: 120 shock waves per minute
Number of subjects: 100
Study: 12859304

Group type: COMPARATOR
Intervention: Control Group (CG) - Patients received a tape containing 20 words played before the start of anaesthesia.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - Patients received propofol at a calculated concentration associated with loss of consciousness (LOC) and a tape was played during this state.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Reference Group (RG) - Patients did not receive the tape.
Number of subjects: 60
Study: 11063952

Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg orally twice a day)
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg orally 3 times a day)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 698
Study: 9033154

Group type: EXPERIMENTAL
Intervention: Involuntary outpatient commitment (OPC) combined with community-based case management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8500233

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 1427
Study: 3328905

Group type: EXPERIMENTAL
Intervention: True Auriculo-electropuncture (AEP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: False Auriculo-electropuncture (control)
Number of subjects: 16
Study: 28982550

Group type: EXPERIMENTAL
Intervention: L-carnitine (3000 mg/d)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study: 27046546

Group type: EXPERIMENTAL
Intervention: Computer-based anti-smoking game
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer-based anti-smoking game with avatar resembling self
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (anti-smoking game without avatar)
Number of subjects: 0
Study: 26717658

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (6 ml/kg as a single bolus over 10-15 min, maximum of 2 boluses)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline
Number of subjects: 44

Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 44
Study: 23114184

Group type: EXPERIMENTAL
Intervention: 15-degree reverse Trendelenburg position (RTP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Horizontal position (HP)
Number of subjects: 64
Study: 20606833

Group type: EXPERIMENTAL
Intervention: d‐ACEIs (enalapril, lisinopril, ramipril)
Number of subjects: 120

Group type: COMPARATOR
Intervention: p‐ACEIs (fosinopril)
Number of subjects: 120
Study: 17822879

Group type: EXPERIMENTAL
Intervention: Lidocaine with clonidine (15 microg/ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine with epinephrine (12.5 microg/ml)
Number of subjects: 40
Study: 16054717

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 12842527

Group type: EXPERIMENTAL
Intervention: Balanced ultrafiltration plus modified ultrafiltration during CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional CPB without ultrafiltration
Number of subjects: 30
Study: 9887063

Group type: COMPARATOR
Intervention: Inhaled budesonide (800 micrograms twice daily for 4 weeks)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dexamethasone (various concentrations)
Number of subjects: 11
Study: 8777366

Group type: EXPERIMENTAL
Intervention: Solution A with 2.5% glucose and 70 mmol Na+
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Solution B with 5.5% glucose and 100 mmol Na+
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both solutions
Number of subjects: 24
Study: 2057198

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 76

Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 76
Study: 7173300

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (Nicorette 4 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 8
Study: 31122995

Group type: EXPERIMENTAL
Intervention: Proactive medical and social intervention
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 1600
Study: 30307821

Group type: EXPERIMENTAL
Intervention: Moderate continuous exercise (CONT) at 70% HRpeak for 60 min/day over 2 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (INT) with 3 min at 90% HRpeak and 3 min at 50% HRpeak for 60 min/day over 2 weeks
Number of subjects: 31
Study: 26975053

Group type: EXPERIMENTAL
Intervention: Consumption of animal source foods (ASF)
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Child Feeding Index (CFI)
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Lower length and weight
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Anemia prevalence in 6- to 12-month-olds
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Ferritin and sTfR levels
Number of subjects: 928
Study: 25193991

Group type: EXPERIMENTAL
Intervention: Lucitanib (doses from 5 to 30 mg)
Number of subjects: 76
Study: 21377114

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg BID
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg BID
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 18339384

Group type: EXPERIMENTAL
Intervention: Highly purified menotropin (HP-hMG, Menopur)
Number of subjects: 986

Group type: COMPARATOR
Intervention: Recombinant follitropin alpha (rFSH, Gonal-F)
Number of subjects: 986
Study: 17071297

Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Monopolar electrocautery tonsillectomy
Number of subjects: 67
Study: 15071275

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 458

Group type: COMPARATOR
Intervention: No ICD (control group)
Number of subjects: 458
Study: 11205195

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (600 mg/m2/d at the first course, 700 mg/m2/d at the second and 800 mg/m2/d at the third course) and l‐folinic acid (150 mg/m2/d) or dl‐folinic acid (300 mg/m2/d) chronomodulated from 22:00 to 10.00 am with peak delivery rate at 4.00 for 5 days every 21 days
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and folinic acid treatment
Number of subjects: 43
Study: 8939037

Group type: EXPERIMENTAL
Intervention: Thinking about propositions implying positive or negative judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knowledge about the target's role (active agent vs. passive recipient role)
Number of subjects: 0
Study: 1358243

Group type: EXPERIMENTAL
Intervention: Alfuzosin 1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alfuzosin 2.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alfuzosin 5 mg
Number of subjects: 12
Study: 4065773

Group type: EXPERIMENTAL
Intervention: Shock-absorbing orthotic device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonorthotic group
Number of subjects: 0
Study: 29617976

Group type: EXPERIMENTAL
Intervention: Tenapanor (3 or 30 mg once daily, or 1, 3, 10 or 30 mg twice daily)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 27739231

Group type: EXPERIMENTAL
Intervention: DW1029M (300 mg × 2T twice daily) with metformin (500 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DW1029M (300 mg × 2T twice daily) with losartan (50 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DW1029M (300 mg × 2T twice daily) with linagliptin (5 mg once daily)
Number of subjects: 0
Study: 26037731

Group type: EXPERIMENTAL
Intervention: Inpatient initiation
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Outpatient initiation
Number of subjects: 1015
Study: 24021824

Group type: EXPERIMENTAL
Intervention: Complex deacon-tetra (N1,3-triazole,кN2) copper (II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No relation (control group 4)
Number of subjects: 30
Study: 21985286

Group type: EXPERIMENTAL
Intervention: Scalloped group
Number of subjects: 93

Group type: COMPARATOR
Intervention: Smooth group
Number of subjects: 93

Group type: COMPARATOR
Intervention: Rough group
Number of subjects: 93
Study: 19496782

Group type: EXPERIMENTAL
Intervention: Locoregional treatment (mastectomy or breast conserving surgery with level I‐II axillary clearance) followed by radiation therapy to the whole breast and standard systemic therapy.
Number of subjects: 271

Group type: COMPARATOR
Intervention: No locoregional treatment, standard systemic therapy given immediately after randomization.
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Locoregional treatment (mastectomy or breast conserving surgery)
Number of subjects: 271

Group type: COMPARATOR
Intervention: No locoregional treatment
Number of subjects: 271
Study: 16779463

Group type: EXPERIMENTAL
Intervention: Paper stamp checklist tool
Number of subjects: 104
Study: 15547162

Group type: EXPERIMENTAL
Intervention: Lower in-treatment left ventricular mass index
Number of subjects: 941
Study: 11122825

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy or chemoradiotherapy before surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemoradiotherapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 9113931

Group type: EXPERIMENTAL
Intervention: Pancreatic-enzyme supplements (mean dose 50,046 units of lipase per kg per day)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (mean dose 18,985 units of lipase per kg per day)
Number of subjects: 134
Study: 8478316

Group type: EXPERIMENTAL
Intervention: Dirithromycin 500 mg once daily
Number of subjects: 193

Group type: COMPARATOR
Intervention: Erythromycin 250 mg four times daily
Number of subjects: 193
Study: 3484503

Group type: EXPERIMENTAL
Intervention: Bacterial polysaccharide immune globulin (BPIG) administered intramuscularly at a dose of 0.5-0.6 ml/kg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional immune serum globulin (ISG) administered intramuscularly at a dose of 0.5-0.6 ml/kg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Bacterial polysaccharide immune globulin (BPIG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional immune serum globulin (ISG)
Number of subjects: 54
Study: 29424437

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 27399735

Group type: EXPERIMENTAL
Intervention: Tai Chi training (two 60‐min sessions each week for three months, plus 30 min self‐practice daily)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Brisk walking (30 min every day)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 246
Study: 24724439

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine intraperitoneal infiltration followed by 0.375% ropivacaine rectus sheath block
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine intraperitoneal infiltration followed by 0.375% ropivacaine rectus sheath block
Number of subjects: 53
Study: 21895979

Group type: EXPERIMENTAL
Intervention: SSRI plus bupropion
Number of subjects: 60

Group type: COMPARATOR
Intervention: SSRI plus placebo
Number of subjects: 60
Study: 20805113

Group type: EXPERIMENTAL
Intervention: 100 U/kg unfractionated heparin (UFH)
Number of subjects: 2505

Group type: COMPARATOR
Intervention: 140 U/kg unfractionated heparin (UFH) (historical control)
Number of subjects: 2505
Study: 18175742

Group type: EXPERIMENTAL
Intervention: Low-glycemic-index (LGI) diet for 10 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: High-glycemic-index (HGI) diet for 10 weeks
Number of subjects: 44
Study: 17072885

Group type: EXPERIMENTAL
Intervention: Silymarin (200 mg) tablet 3 times a day plus conventional therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo tablet plus conventional therapy
Number of subjects: 51
Study: 13678228

Group type: EXPERIMENTAL
Intervention: Keishi-bukuryo-gan (KBG) 12 g daily for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pentoxifylline (PXF) 300 mg daily for 4 weeks
Number of subjects: 30
Study: 10997480

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogens (CEE) daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.25 mg conjugated equine estrogens (CEE) daily
Number of subjects: 12
Study: 9361051

Group type: EXPERIMENTAL
Intervention: Standardized method for assessing chest radiographic results
Number of subjects: 805
Study: 1391559

Group type: EXPERIMENTAL
Intervention: cotrimoxazole (29 patients)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: amoxicillin‐clavulanic acid (32 patients)
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo (29 patients)
Number of subjects: 90
Study: 3902679

Group type: EXPERIMENTAL
Intervention: Fructose (1 g/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glucose (1 g/kg)
Number of subjects: 10
Study: 30815856

Group type: EXPERIMENTAL
Intervention: Mephedrone 50 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mephedrone 100 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mephedrone 150 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mephedrone 200 mg
Number of subjects: 9
Study: 29689594

Group type: EXPERIMENTAL
Intervention: B-mode + M-mode ultrasound
Number of subjects: 140

Group type: COMPARATOR
Intervention: B-mode ultrasound alone
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: M-mode ultrasound in providers with fewer than 250 scans
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: B-mode + M-mode ultrasound in providers with more than 250 scans
Number of subjects: 140
Study: 27101728

Group type: EXPERIMENTAL
Intervention: Sublobar resection (SR)
Number of subjects: 69
Study: 24843066

Group type: EXPERIMENTAL
Intervention: MD2Me intervention (2-month intensive Web-based and text-delivered disease management and skill-based intervention followed by a 6-month review period)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: MD2Me intervention
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (mailed materials on general health topics)
Number of subjects: 81
Study: 22571951

Group type: EXPERIMENTAL
Intervention: Increase in depressive symptoms after myocardial infarction
Number of subjects: 767

Group type: COMPARATOR
Intervention: Non-depressed patients
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 767
Study: 20194251

Group type: EXPERIMENTAL
Intervention: Baby videos (infant-directed DVD)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Parent report and observational measures of vocabulary acquisition
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Parent report of general language development
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Parent report of children's media use
Number of subjects: 96
Study: 18580334

Group type: COMPARATOR
Intervention: Fixed iodine-dose protocol (80 mL Iopamidol-370, 20 seconds injection duration)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Weight-adjusted iodine-dose protocol (1.0 mL/kg, 15 seconds injection duration)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Weight-adjusted iodine-dose protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fixed iodine-dose protocol
Number of subjects: 60